* Cel-Sci Corp., of Alexandria, Va., released preliminary results of a 10-patient clinical trial of Multikine in head and neck cancer. Patients displayed one or more beneficial responses during the three-week treatment period prior to surgery, consisting of reduction in tumor size, resolution of tumor ulceration, reduction or elimination of local pain, and increased tongue mobility (in tongue tumors).

* OraVax Inc., of Cambridge, Mass., will participate in a defense contract awarded to DynPort LLC, of Reston, Va., for the development and manufacture of vaccines to protect U.S. armed forces against potential biological warfare agents. OraVax expects to manufacture several vaccines at its Canton, Mass., factory.

No Comments